Safety and Efficacy Study of A0001 in Patients With the A3243G Mitochondrial DNA Point Mutation
Status:
Terminated
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
This is a phase 2a, double-blind, placebo-controlled, single-center study. Twenty-one
patients who qualify for the study will be randomly assigned to either active drug or
placebo. The study will take place at Newcastle University. Patients will have a 66% chance
of getting active drug. Patients will be required to take study treatment orally twice a day
for 28 days. A baseline visit will occur within 21 days of screening visit. All patients will
be followed for 1 week after completion of study or early withdrawal from the study.